<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244125</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2013-05</org_study_id>
    <nct_id>NCT02244125</nct_id>
  </id_info>
  <brief_title>A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial</brief_title>
  <acronym>PCD</acronym>
  <official_title>A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intergroupe Francophone du Myelome</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Imnovid in combination with dexamethasone is indicated in the treatment of adult patients&#xD;
      with relapsed and refractory multiple myeloma who have received at least two prior treatment&#xD;
      regimens, including both lenalidomide (Revlimid) and bortezomib (Velcade), and have&#xD;
      demonstrated disease progression on the last therapy.&#xD;
&#xD;
      Patients with relapsed and refractory multiple myeloma who have received bortezomib,&#xD;
      lenalidomide, dexamethasone combination, considered to be the multiple myeloma optimal&#xD;
      treatment, can access to pomalidomide under marketing authorization only as from third line&#xD;
      of treatment.&#xD;
&#xD;
      In France this combination is not authorized for marketing for a first line treatment and&#xD;
      only patient randomized in the IFM/DFCI 2009 trial received it.&#xD;
&#xD;
      This study concerns patients previously randomized in the IFM/DFCI 2009 trial who have&#xD;
      received bortezomib, lenalidomide and Dexamethasone combination in first line, which at&#xD;
      progression/relapse time therapeutic opportunities remained limited and who cannot access&#xD;
      pomalidomide under marketing authorization.&#xD;
&#xD;
      This study is a multicentre, phase 2, open label, study testing the triple combination of&#xD;
      pomalidomide and cyclophosphamide and dexamethasone (PCD) in multiple myeloma patients who&#xD;
      are refractory or in first progression/relapse after a first line treatment with bortezomib&#xD;
      and lenalidomide, an IMiDs (an Immuno Modulatory Drug and a proteasome inhibitor) according&#xD;
      to the IFM/DFCI 2009 trial.&#xD;
&#xD;
      In the IFM/DFCI trial, patients in arm A received eight cycles of the&#xD;
      Velcade-Revlimid-Dexamethasone combination followed by 1 year of lenalidomide maintenance,&#xD;
      patients in arm B received 3 cycles of Velcade-Revlimid-Dexamethasone combination plus&#xD;
      melphalan 200mg/m2 with an autologous transplantation followed by 2 cycles of&#xD;
      Velcade-Revlimid-Dexamethasone combination consolidation and 1 year of lenalidomide&#xD;
      maintenance.&#xD;
&#xD;
      This study will contain 3 treatment phases:&#xD;
&#xD;
        -  Study treatment phase:&#xD;
&#xD;
      All patients will receive 4 cycles (28 days) of pomalidomide-cyclophosphamide-dexamethasone&#xD;
      combination.&#xD;
&#xD;
        -  Consolidation phase (depends on the initial randomization in the IFM/DFCI 2009 trial):&#xD;
&#xD;
             -  For patients previously randomized in IFM/DFCI 2009's arm A:&#xD;
&#xD;
                  -  Melphalan 200 mg/m2 followed by Autologous Transplantation&#xD;
&#xD;
                  -  Three months after, 2 cycles of pomalidomide-cyclophosphamide-dexamethasone&#xD;
                     combination&#xD;
&#xD;
             -  For patients previously randomized in IFM/DFCI 2009's arm B:&#xD;
&#xD;
                  -  5 cycles of pomalidomide-cyclophosphamide-dexamethasone combination&#xD;
&#xD;
        -  Maintenance phase (identical to all patients) subsequent cycles of pomalidomide and&#xD;
           Dexamethasone until progression / relapse or discontinuation for any other reason.&#xD;
&#xD;
      For arm B patients, in case relapse occurs at least 12 months after the end of the&#xD;
      maintenance IFM/DFCI 2009 trial, they could proceed to a second autologous transplantation&#xD;
      and therefore follow the arm A procedure. The decision to proceed to a second transplant will&#xD;
      be made by the physician and the patient.&#xD;
&#xD;
      In order to have the same amount of patients enrolled in this trial in the initial Arm A and&#xD;
      Arm B of the IFM/DFCI 2009 trial, once 50 patients have been included in either arm A or B,&#xD;
      subsequent patients will be eligible if they have not been initially treated as the first 50&#xD;
      patients from either arm.&#xD;
&#xD;
      The primary endpoint is the response rate (Partial Response (PR) or better) after 4 cycles of&#xD;
      the triple combination pomalidomide and cyclophosphamide and dexamethasone (PCD) in the&#xD;
      studied population using International Myeloma Working Group (IMWG) response criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (Partial response (PR) or better)</measure>
    <time_frame>4 months after treatment initiation</time_frame>
    <description>after 4 cycles of the triple association</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety : incidence of Adverse Events and Serious Adverse Events and laboratory abnormalities</measure>
    <time_frame>from consent to 28 days after the last dose</time_frame>
    <description>using National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTC AE) V4.03</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to response and response duration</measure>
    <time_frame>every 28 days until progression/relapse or discontinuation</time_frame>
    <description>Time to response (from the date of inclusion to the date of the first observation of response) and response duration (time between first documentation of response and disease progression).</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>every 28 days until progression/relapse or discontinuation</time_frame>
    <description>from first dose to first observation of disease progression</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years from last study drug intake</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>First Relapse</condition>
  <arm_group>
    <arm_group_label>Previous IFM/DFCI 2009 arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients previously randomized into IFM/DFCI 2009 trial arm A (or if transplantation was not done) will receive:&#xD;
The treatment phase:&#xD;
4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)&#xD;
The consolidation phase:&#xD;
Melphalan 200mg/m2 followed by ASCT (Autologous Stem Cell Transplantation)&#xD;
2 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)&#xD;
The maintenance phase: Until progression or discontinuation for any other reason&#xD;
Pomalidomide and Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previous transplantation IFM/DFCI 2009 arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients previously randomized into IFM/DFCI 2009 trial arm B (RVD plus Transplant) will receive:&#xD;
The treatment phase:&#xD;
4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)&#xD;
The consolidation phase:&#xD;
5 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)&#xD;
The maintenance phase: Until progression or discontinuation for any oher reason&#xD;
Pomalidomide and Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCD</intervention_name>
    <description>STUDY TREATMENT PHASE: All patients&#xD;
4x 28 days cycles of PCD&#xD;
[Pomalidomide: 4mg/day oral route on 21 days per cycle]&#xD;
[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]&#xD;
[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle]&#xD;
CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:&#xD;
Arm A:&#xD;
Melphalan 200mg/m2 followed by Autologous Transplantation&#xD;
2x 28 days cycles of PCD, three months post transplantation&#xD;
Arm B:&#xD;
5x 28 days cycles of PCD&#xD;
[Pomalidomide: 4mg/day oral route on 21 days per cycle]&#xD;
[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]&#xD;
[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle]&#xD;
MAINTENANCE PHASE: All patients&#xD;
- Until progression/relapse or discontinuation for any other reason&#xD;
[Pomalidomide: 4mg/day oral route on 21 days per cycle]&#xD;
[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle]</description>
    <arm_group_label>Previous IFM/DFCI 2009 arm A</arm_group_label>
    <arm_group_label>Previous transplantation IFM/DFCI 2009 arm B</arm_group_label>
    <other_name>Pomalidomide-Cyclophosphamide-Dexamethasone association</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous transplantation (ASCT)</intervention_name>
    <description>Arm A:&#xD;
•Melphalan 200mg/m2 followed by Autologous Transplantation</description>
    <arm_group_label>Previous transplantation IFM/DFCI 2009 arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have been treated in first line within the IFM/DFCI 2009 trial to be&#xD;
             treated within the PCD trial in second line&#xD;
&#xD;
          2. Must be able to understand and voluntarily sign an informed consent form&#xD;
&#xD;
          3. Must be able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          4. Age: 18-70 years&#xD;
&#xD;
          5. Life expectancy &gt;6 months&#xD;
&#xD;
          6. Patients must have progressive (+/- symptomatic) Myeloma as defined by the IMWG&#xD;
             criteria with increase of ≥25% from lowest response value in any one or more of the&#xD;
             following:&#xD;
&#xD;
               -  Serum M-component and/or (the absolute increase must be ≥0.5 g/dl)&#xD;
&#xD;
               -  Urine M-component and/or (the absolute increase must be ≥200 mg/24h)&#xD;
&#xD;
               -  Only in patients without measurable serum and urine M-protein levels: the&#xD;
                  difference between involved and uninvolved FLC levels. The absolute increase must&#xD;
                  be &gt;10 mg/dl&#xD;
&#xD;
               -  Bone marrow plasma cell percentage; the absolute percentage must be ≥10%&#xD;
&#xD;
               -  Definite development of new bone lesions or soft tissue plasmacytomas or definite&#xD;
                  increase in the size of existing bone lesions or soft tissue plasmacytomas&#xD;
&#xD;
               -  Development of hypercalcaemia (corrected serum calcium &gt;11.5 mg/dl or 2.65mmol/l)&#xD;
                  that can be attributed solely to the plasma cell proliferative disorder.&#xD;
&#xD;
          7. Patients must have a clearly detectable and quantifiable monoclonal M-component value:&#xD;
&#xD;
               -  IgG (serum M-component &gt;10g/l)&#xD;
&#xD;
               -  IgA (serum M-component &gt;5g/l)&#xD;
&#xD;
               -  IgD (serum M-component &gt;0.5g/l)&#xD;
&#xD;
               -  Light chain (serum M-component &gt;1g/l or Bence Jones &gt;200mg/24h)&#xD;
&#xD;
               -  In patients without measurable serum and urine M-protein levels and in the&#xD;
                  absence of renal failure: when the absolute serum FreeLightChain (sFLC) is&#xD;
                  ≥100mg/l and an abnormal sFLC K/λ ratio (&lt;0.26 or&gt;1.65) is found.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2&#xD;
&#xD;
          9. Adequate bone marrow function, documented within 96 hours prior to treatment without&#xD;
             transfusion or growth factor support, defined as:&#xD;
&#xD;
               -  Absolute neutrophils ≥1000/mm3&#xD;
&#xD;
               -  Platelets ≥75000/mm3&#xD;
&#xD;
               -  Hemoglobin ≥8.5g/dl&#xD;
&#xD;
         10. Adequate organ function, documented within 96 hours prior to treatment, defined as:&#xD;
&#xD;
               -  Serum SGOT/AST or SGPT/ALT &lt;3.0 X Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Serum creatinine clearance (Cockcroft-Gault formula) ≥50 ml/min&#xD;
&#xD;
               -  Serum total bilirubin &lt;2.0 mg/dl&#xD;
&#xD;
         11. Wash out period of at least 2 weeks from previous antitumor therapy or any&#xD;
             investigational treatment.&#xD;
&#xD;
         12. Able to take antithrombotic medicines such as low molecular weight heparin or aspirin.&#xD;
&#xD;
         13. Subjects affiliated with an appropriate social security system&#xD;
&#xD;
         14. Agree to abstain from donating blood while taking study drug therapy and for at least&#xD;
             28 days following discontinuation of study drug therapy&#xD;
&#xD;
         15. Agree not to share study medication with another person and to return all unused study&#xD;
             drug to the investigator&#xD;
&#xD;
         16. Female subjects of childbearing potential (*) must:&#xD;
&#xD;
               -  Understand the potential teratogenic risk to the unborn child&#xD;
&#xD;
               -  Understand the need and agree to use, and be able to comply with, two reliable&#xD;
                  forms of contraception simultaneously or to practice complete abstinence from&#xD;
                  heterosexual contact during the following time periods related to this study:&#xD;
&#xD;
                    1. for at least 28 days before starting study drug;&#xD;
&#xD;
                    2. while participating in the study;&#xD;
&#xD;
                    3. dose interruptions; and&#xD;
&#xD;
                    4. for at least 28 days after study treatment discontinuation.&#xD;
&#xD;
             The two methods of reliable contraception must include one highly effective method and&#xD;
             one additional effective (barrier) method. Females of childbearing potential must be&#xD;
             referred to a qualified provider of contraceptive methods if needed. The following are&#xD;
             examples of highly effective and additional effective methods of contraception:&#xD;
&#xD;
               -  Highly effective methods:&#xD;
&#xD;
                    -  Intrauterine device (IUD)&#xD;
&#xD;
                    -  Hormonal (birth control pills, injections, implants)&#xD;
&#xD;
                    -  Tubal ligation&#xD;
&#xD;
                    -  Partner's vasectomy&#xD;
&#xD;
               -  Additional effective methods:&#xD;
&#xD;
                    -  Male condom&#xD;
&#xD;
                    -  Diaphragm&#xD;
&#xD;
                    -  Cervical Cap&#xD;
&#xD;
             Because of the increased risk of venous thromboembolism in patients with multiple&#xD;
             myeloma taking pomalidomide and cyclophosphamide and dexamethasone, combined oral&#xD;
             contraceptive pills are not recommended. If a female subject is currently using&#xD;
             combined oral contraception the patient should switch to another one of the highly&#xD;
             effective methods listed above. The risk of venous thromboembolism continues for 4-6&#xD;
             weeks after discontinuing combined oral contraception. The efficacy of contraceptive&#xD;
             steroids may be reduced during co-treatment with dexamethasone.&#xD;
&#xD;
             Implants and levonorgestrel-releasing intrauterine devices are associated with an&#xD;
             increased risk of infection at the time of insertion and irregular vaginal bleeding.&#xD;
             Prophylactic antibiotics should be considered particularly in patients with&#xD;
             neutropenia.&#xD;
&#xD;
             o Agree to have pregnancy testing based on the frequency outlined below.&#xD;
&#xD;
             Medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/ml must be&#xD;
             performed for females of childbearing potential, including females of childbearing&#xD;
             potential who commit to complete abstinence:&#xD;
&#xD;
               -  Before starting study drug: females of childbearing potential must have two&#xD;
                  negative pregnancy tests prior to starting study drug. The first pregnancy test&#xD;
                  must be performed within 10-14 days prior to the start of study drug and the&#xD;
                  second pregnancy test must be performed within 24 hours prior to the start of&#xD;
                  study drug. The patient may not receive study drug until the study doctor has&#xD;
                  verified that the results of these pregnancy tests are negative.&#xD;
&#xD;
               -  During study participation and for 28 days following study drug discontinuation:&#xD;
&#xD;
             Females of childbearing potential with regular or no menstrual cycles must agree to&#xD;
             have pregnancy tests weekly for the first 28 days of study participation and then&#xD;
             every 28 days while on study, at study discontinuation, and at day 28 following study&#xD;
             drug discontinuation.&#xD;
&#xD;
             If menstrual cycles are irregular, the pregnancy testing must occur weekly for the&#xD;
             first 28 days and then every 14 days while on study, at study discontinuation, and at&#xD;
             days 14 and 28 following study drug discontinuation.&#xD;
&#xD;
             *Criteria for women of childbearing potential: This protocol defines a female of&#xD;
             childbearing potential as a sexually mature woman who: 1) has not undergone a&#xD;
             hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal&#xD;
             (amenorrhea following cancer therapy does not rule out childbearing potential) for at&#xD;
             least 24 consecutive months (ie, has had menses at any time in the preceding 24&#xD;
             consecutive months).&#xD;
&#xD;
         17. Male subjects must:&#xD;
&#xD;
               -  Practice complete abstinence or agree to use a condom during sexual contact with&#xD;
                  a pregnant female or a female of childbearing potential while participating in&#xD;
                  the study, during dose interruptions and for at least 28 days following study&#xD;
                  drug discontinuation, even if he has undergone a successful vasectomy.&#xD;
&#xD;
               -  Agree not to donate semen or sperm during study drug therapy and for at least 28&#xD;
                  days following discontinuation of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other uncontrolled medical condition or comorbidity that might interfere with&#xD;
             subject's participation&#xD;
&#xD;
          2. Primary amyloidosis or myeloma complicated by amyloidosis&#xD;
&#xD;
          3. Pregnant or breast feeding females&#xD;
&#xD;
          4. Use of any other experimental drug or therapy within 2 weeks before study treatment&#xD;
             initiation (except local radiotherapy and/or corticosteroid until dose of&#xD;
             dexamethasone 160mg)&#xD;
&#xD;
          5. Known positive for HIV or Active infectious hepatitis, type B or C&#xD;
&#xD;
          6. Patients with non-secretory MM&#xD;
&#xD;
          7. Prior history of malignancies within 10 years&#xD;
&#xD;
          8. Evidence of Central Nervous System (CNS) involvement&#xD;
&#xD;
          9. Any &gt;grade 2 toxicity unresolved&#xD;
&#xD;
         10. Peripheral neuropathy &gt;grade 2&#xD;
&#xD;
         11. Known hypersensitivity to thalidomide, lenalidomide, cyclophosphamide or dexamethasone&#xD;
&#xD;
         12. Ongoing active infection, especially ongoing pneumonitis&#xD;
&#xD;
         13. Participant with clinical signs of heart or coronary failure, or evidence of Left&#xD;
             Ventricular Ejection Fraction (LVEF) inferior to 40%.&#xD;
&#xD;
             Participant with myocardial infarction within 6 months prior to enrolment or have New&#xD;
             York Heart Association (NYHA) Class III or IV heart failure, and controlled angina,&#xD;
             severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities&#xD;
&#xD;
         14. Inability or unwillingness to comply with birth control requirements&#xD;
&#xD;
         15. Unable to take antithrombotic medicines at study entry&#xD;
&#xD;
         16. Unable to take corticotherapy at study entry&#xD;
&#xD;
         17. Scheduled vaccination with a live agent such as yellow fever vaccine&#xD;
&#xD;
         18. Individually deprived of liberty or placed under the authority of a tutor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KUHNOWSKI Frederique, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICH - Hôpital A. Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie de Basse Normandie - IHBN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier départemental de Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>750005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Yves Le Foll</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse-Oncopôle (IUCT-O)</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopitaux de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>September 8, 2014</study_first_submitted>
  <study_first_submitted_qc>September 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2014</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapse</keyword>
  <keyword>Refractory</keyword>
  <keyword>PCD</keyword>
  <keyword>IFM/DFCI 2009</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Autologous</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Immunoglobulin</keyword>
  <keyword>Ig</keyword>
  <keyword>Free light Chain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

